Apixaban in Patients With Left Ventricular Thrombus

Apixaban in Patients With Left Ventricular Thrombus Post Myocardial Infarction; A Randomized Clinical Trial

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05208398

Enrollment

Registered

2022-01-26

Start date

2018-02-18

Completion date

2021-09-30

Last updated

2022-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Left Ventricular Thrombus

Brief summary

Open label randomized controlled clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in treating left ventricular thrombus in patients with acute or recent myocardial infarction (MI).

Interventions

DRUGApixaban

5 mg twice daily, on top of standards of care.

DRUGWarfarin

Warfarin, oral tablets, to achieve international normalized ratio (INR) of 2-3, on top of standards of care, as per updated guidelines of acue coronary syndrome management recommendations

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Intervention model description

Open label randomized controlled clinical trial, two parallel active groups, with blinded primary study outcome assessor.

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

All the following criteria must be fulfilled: * Ages between 18 and 80 years, * History of anterior wall MI, either acute (within a week) or recent (within a month) * Evident left ventricular thrombus (LVT) by transthoracic echocardiography, * Naïve to oral anticoagulants (OAC) * stable to start OAC

Exclusion criteria

* Other indications for OAC, * Patients with contraindications for OAC, * Right ventricular thrombus or atrial thrombus, * History of confirmed stroke or other systemic embolization within the previous six months, * High bleeding risk, * Severe renal impairment, * Patients with expected difficulties to follow the INR strictly.

Design outcomes

Primary

Measure	Time frame	Description
Resolution of left ventricular thrombus	3 months	Transthoracic, noncontrast, echocardiographic assessment.

Secondary

Measure	Time frame	Description
Resolution of left ventricular thrombus	6 months	Transthoracic, noncontrast, echocardiographic assessment.
Safety outcome	3-6 months	Major Adverse Cardiovascular Events (MACE) or any relevant bleeding according to the Bleeding Academic Research Consortium (BARC) classification

Countries

Saudi Arabia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026